How much funding has J-Pharma raised?

J-Pharma has raised $25.9M in total funding, most recently a Series D round.

Where is J-Pharma headquartered?

J-Pharma is headquartered in Tokyo, Japan.

J-Pharma

Q: Who are J-Pharma's investors?

J-Pharma's investors include JIC Venture Growth Investments, Eight Roads Ventures, F-Prime Capital.

IPO

Developing innovative new drugs targeting SLC transporters

Tokyo, Japan · Founded 2005 · $25.9M raised

Biotech

Headquarters: Tokyo
Employees: 1–10
Founded: 2005
Business Model: B2B

Website: j-pharma.com
Total Funding: $25.9M
Last Round: $4.8M Series DOct 2023
Rounds: 3

About

J-Pharma Co., Ltd. is a Tokyo-based clinical-stage biopharmaceutical company founded in December 2005, focused on developing novel drugs that target SLC (solute carrier) membrane transporters to address unmet medical needs. The company's lead compound, Nanvuranlat (JPH203), is a first-in-class LAT1 inhibitor currently in global Phase III clinical trials for the second-line treatment of biliary tract cancer, having received FDA Orphan Drug Designation in 2022 and FDA IND clearance in 2024. J-Pharma also advances JPH034, a CNS-penetrant LAT1 inhibitor entering Phase I trials for multiple sclerosis. The company was founded based on research by Hitoshi Endou at Kyorin University and listed on the Tokyo Stock Exchange Growth Market in March 2026.

Summary

J-Pharma is a Biotech company based in Tokyo, Japan, founded in 2005. It has raised $25.9M in total across 3 rounds, most recently a $4.8M Series D round in Oct 2023. Investors include JIC Venture Growth Investments, Eight Roads Ventures and F-Prime Capital.